NAPSR news: Abbvie has successful second quarter as Humira sales climb

WASHINGTON - July 28, 2014 - PRLog -- Abbvie joins the list of pharmaceutical companies boasting a successful second quarter. The company released its Q2 report on July 25, 2014 with worldwide sales amounting to $4.926 billion in the second quarter, up 5.0 percent.  Sales increased 4.8 % on an operational basis excluding a 0.2 percent favorable impact from foreign exchange rate fluctuation.

Humira sales had a major impact on the revenue growth increasing 26.2 %, or 25.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations. Other contributors to Abbvie’s successful quarter include: Synthroid, Sevoflurane and Duodopa

“This was another very strong quarter for AbbVie, as we delivered sales and earnings per share above our original guidance and announced plans to merge with Shire, a strategic action that will further enhance our long‐term growth prospects,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.  “Last month, we raised our 2014 earnings‐per‐share guidance, reflecting strong underlying business performance.  We continue to expect positive trends for the second half of the year, as well as additional progress from our pipeline, including the expected U.S. approval of our interferon‐free HCV combination.”

The company's commitment to merge with Shire will create a larger and more diversified biopharmaceutical company. Other notable achievments in the second quarter stemmed from various therapeutic breakthroughs which included a Priority Review (FDA) and Accelerated Assessment (EMA) of Abbvie's investigational, all‐oral, interferon‐free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus (HCV).

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability from their successful product pipeline, they will need both certified and qualified individuals to promote their diversified therapeutic portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives (NAPSRx) for more information.